[go: up one dir, main page]

JPH06113828A - Additive composition for serum-free medium - Google Patents

Additive composition for serum-free medium

Info

Publication number
JPH06113828A
JPH06113828A JP4270531A JP27053192A JPH06113828A JP H06113828 A JPH06113828 A JP H06113828A JP 4270531 A JP4270531 A JP 4270531A JP 27053192 A JP27053192 A JP 27053192A JP H06113828 A JPH06113828 A JP H06113828A
Authority
JP
Japan
Prior art keywords
serum
fraction
additive composition
medium
free medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4270531A
Other languages
Japanese (ja)
Inventor
Masamitsu Yonekura
政実 米倉
Noriyuki Washino
憲之 鷲野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
API KK
Original Assignee
API KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by API KK filed Critical API KK
Priority to JP4270531A priority Critical patent/JPH06113828A/en
Publication of JPH06113828A publication Critical patent/JPH06113828A/en
Pending legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PURPOSE:To provide the subject additive composition for a serum-free medium, capable of exhibiting an excellent cell growth promotion activity, of efficiently culturing cells and of readily separating and purifying the produced useful materials while keeping the constant quality at low cost. CONSTITUTION:This additive composition for a serum-free cell culture medium contains royal jelly-derived proteins, especially the DIII fraction obtained by isolating through an ion-exchange column. This DIII fraction is added in an amount within the range of 0.1mug/ml to 4mg/ml to an eRDF medium as a serum- free medium containing amino acids, sugars and vitamins. If human monocytoid cell (U937) is cultured in this culture medium, an excellent cell growth promotion effect is exhibited.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】この発明は、例えば動物細胞培養
のための無血清培地に添加されることにより、細胞増殖
促進効果等を示す無血清培地用添加組成物に関するもの
である。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an additive composition for a serum-free medium which exhibits a cell growth promoting effect and the like when added to a serum-free medium for culturing animal cells, for example.

【0002】[0002]

【従来の技術】従来、動物細胞による有用物質生産の際
には、生産性を上げるために10%程度の動物血清を添
加した培地が使用されてきた。
2. Description of the Related Art Conventionally, in the production of useful substances by animal cells, a medium supplemented with about 10% of animal serum has been used in order to improve productivity.

【0003】[0003]

【発明が解決しようとする課題】ところが、このような
培地中には高濃度の血清由来の蛋白質が含まれてしまう
ために、得られる生成液から有用物質を取り出すための
精製法が複雑となる。しかも、動物血清は製造ロットに
よる品質の差が大きく、必ずしも安定供給されておら
ず、高価でもあることから、動物細胞による有用物質の
生産コストを上昇させる要因にもなっているという問題
があった。
However, since such a medium contains a high concentration of protein derived from serum, the purification method for taking out a useful substance from the obtained product solution becomes complicated. . Moreover, animal serum has a large difference in quality depending on the production lot, is not always stably supplied, and is expensive, which causes a problem of increasing the production cost of useful substances by animal cells. .

【0004】この発明はこのような従来の問題に着目し
てなされたものであって、その目的は、優れた細胞増殖
促進活性等の細胞培養活性を発揮して効率的な細胞培養
ができると共に、生産された有用物質の分離、精製を容
易に行うことができ、しかも低コストで安定した品質の
ものを供給可能な無血清培地用添加組成物を提供するこ
とにある。
The present invention has been made in view of such conventional problems, and an object thereof is to exert an excellent cell culture activity such as a cell growth promoting activity and enable efficient cell culture. Another object of the present invention is to provide an additive composition for serum-free medium, which can easily separate and purify the produced useful substance, and can supply stable quality at low cost.

【0005】[0005]

【課題を解決するための手段】上記目的を達成するため
に、この発明の細胞培養のための無血清培地用添加組成
物はローヤルゼリー由来の蛋白質を含有することを特徴
とする。
To achieve the above object, the additive composition for serum-free medium for cell culture of the present invention is characterized by containing a protein derived from royal jelly.

【0006】次に、この発明についてさらに詳細に説明
する。ローヤルゼリーは蜜蜂が作り出すもので、女王蜂
はこのローヤルゼリーのみを摂取して生命を営み、膨大
な量の卵を生む。これは、ローヤルゼリーが完全食品と
いわれているように栄養豊かで多岐にわたる生理作用を
有するためである。即ち、この生理作用は抗癌作用、抗
腫瘍作用、創傷治癒促進作用、抗菌作用、抗糖尿病作
用、血流増加作用、抗動脈硬化作用、発育促進作用など
である。このことは、ローヤルゼリー中に生理活性物質
が存在していることを意味している。このような点に着
目して、ローヤルゼリーは健康食品、化粧品、医薬品等
として利用されている。
Next, the present invention will be described in more detail. Royal jelly is produced by bees, and the queen bee ingests only this royal jelly for life, and produces a huge number of eggs. This is because royal jelly has a rich nutritional and diverse physiological action, which is said to be a complete food. That is, this physiological action is an anticancer action, an antitumor action, a wound healing promoting action, an antibacterial action, an antidiabetic action, a blood flow increasing action, an anti-atherogenic action, a growth promoting action and the like. This means that the physiologically active substance is present in the royal jelly. Focusing on these points, royal jelly is used as health foods, cosmetics, pharmaceuticals, and the like.

【0007】動物細胞培養において、このようなローヤ
ルゼリー中の蛋白質画分を各種無血清培地に添加するこ
とにより、最良の増殖促進効果が得られる。即ち、ロー
ヤルゼリーから蛋白質を分離精製し、得られた蛋白質を
培地の量に対して0.1 μg /mlから4mg/mlの範囲で添
加すれば、効率的な各種細胞培養を行うことができる。
そして、生産物からの有用物質の分離も容易である。従
って、従来用いられてきた蛋白質性の成長促進因子、例
えばインシュリン、牛胎児血清、サイトカイン類等の蛋
白質成分を加えることなく、細胞培養を効果的に行うこ
とができる。
In animal cell culture, the best growth promoting effect can be obtained by adding the protein fraction in such royal jelly to various serum-free media. That is, various proteins can be efficiently cultured by separating and purifying proteins from royal jelly and adding the obtained proteins in the range of 0.1 μg / ml to 4 mg / ml with respect to the amount of medium.
And, it is easy to separate the useful substance from the product. Therefore, the cell culture can be effectively performed without adding the conventionally used proteinaceous growth-promoting factors such as insulin, fetal bovine serum, and protein components such as cytokines.

【0008】ローヤルゼリー中の蛋白質、即ち増殖促進
活性を示す因子は以下のように容易に分離精製すること
ができる。即ち、常法により得られた蛋白質画分をゲル
濾過、イオン交換クロマトグラフィ、疎水性クロマトグ
ラフィ、電気泳動、逆相カラムクロマト等を用いた高速
液体クロマトグラフィ等の方法により高収率で分離精製
される。得られた蛋白質は、例えばイオン交換クロマト
グラフィで分画される。従って、得られたローヤルゼリ
ー由来の蛋白質は、従来の蛋白質性増殖因子よりも単一
のものが得られると共に、製造ロット毎の品質の差が少
なく、低コストで得られる。
The protein in royal jelly, that is, the factor showing the growth promoting activity, can be easily separated and purified as follows. That is, the protein fraction obtained by a conventional method is separated and purified in a high yield by a method such as gel filtration, ion exchange chromatography, hydrophobic chromatography, electrophoresis, high performance liquid chromatography using reversed phase column chromatography and the like. The obtained protein is fractionated by, for example, ion exchange chromatography. Therefore, the obtained protein derived from royal jelly can be obtained as a single protein as compared with the conventional proteinaceous growth factors, and the quality difference between production lots is small, and the protein can be obtained at low cost.

【0009】このようにして、分画されたDI 画分、D
II画分、DIII 画分が得られる。これらの画分のうち、
DIII 画分が最も細胞の増殖促進能が高い。このDIII
画分は等電点が4.4 から5.4 であり、分子量(重量平均
分子量)4万から6万のサブユニット約6個からなる分
子量30万から40万の範囲の糖蛋白質画分である。こ
の糖蛋白質画分は透析後凍結乾燥によって粉末化し、4
℃以下で保存すれば数年間安定性があり、動物細胞増殖
促進作用が保持される。
The DI fraction, D, thus fractionated
Fractions II and DIII are obtained. Of these fractions
The DIII fraction has the highest cell growth promoting ability. This DIII
The fraction is a glycoprotein fraction having an isoelectric point of 4.4 to 5.4 and a molecular weight of 300,000 to 400,000, which is composed of about 6 subunits having a molecular weight (weight average molecular weight) of 40,000 to 60,000. This glycoprotein fraction was dialyzed and lyophilized to give a powder.
If stored at or below ℃, it will be stable for several years, and the activity of promoting animal cell growth will be retained.

【0010】[0010]

【実施例】以下にこの発明を具体化した実施例について
図1,2を用いて説明する。 (実施例1、細胞増殖促進作用を有する糖蛋白質の製造
法)生ローヤルゼリー107gを50mMリン酸緩衝液
(pH6.2 )に混合して、透析即ち半透膜により低分子
化合物を除去し、分子量1万以上の蛋白質画分を得た。
この画分に対して、遠心分離(20000G、20分)
を行い、上清を得た。この上清を予め、上記リン酸緩衝
液で平衡化したイオン交換カラム(DEAE-TOYOPEARL 650
M )に通し、非吸着画分を溶出させた後、吸着画分を塩
化ナトリウムの濃度が0から0.3 Mとなるように直線的
に増加させて、溶出を行った。
Embodiments Embodiments embodying the present invention will be described below with reference to FIGS. (Example 1, production method of glycoprotein having cell growth promoting action) 107 g of raw royal jelly was mixed with 50 mM phosphate buffer (pH 6.2), and low molecular weight compounds were removed by dialysis, that is, a semipermeable membrane to obtain a molecular weight. Over 10,000 protein fractions were obtained.
Centrifugation (20,000 G, 20 minutes) for this fraction
Was performed to obtain a supernatant. This supernatant was preliminarily equilibrated with the above-mentioned phosphate buffer solution using an ion exchange column (DEAE-TOYOPEARL 650
After elution of the non-adsorbed fraction, the adsorbed fraction was linearly increased to a sodium chloride concentration of 0 to 0.3 M for elution.

【0011】その結果、図1に示すように、DI 〜DII
I 画分が得られた。DI 画分は2.24g(蛋白質回収率3
1.4%)、DII画分は 0.2g(蛋白質回収率 2.8%)、
DIII画分は3.15g(蛋白質回収率44.2%)であった。
なお、イオン交換カラムにおける溶出条件は、次のよう
に設定した。
As a result, as shown in FIG. 1, DI to DII
I fraction was obtained. DI fraction is 2.24 g (protein recovery rate 3
1.4%), DII fraction 0.2g (protein recovery rate 2.8%),
The DIII fraction was 3.15 g (protein recovery rate 44.2%).
The elution conditions in the ion exchange column were set as follows.

【0012】カラムサイズ:1.5cm ×38cm、流速:43.8
ml/hr 、緩衝液(開始):50mMリン酸ナトリウム緩衝液
(pH 6.2) (溶出):50mMリン酸ナトリウム緩衝液(pH
6.2) +0.3mM までの濃度のNaCl また、図1におけるフラクションNoは、1フラクション
No当り5.9ml である。 (試験例1、細胞増殖促進作用の測定法)細胞培養は以
下のように行った。増殖促進作用を調べるための培養細
胞にヒト単球細胞(U937)及びヒト肺癌特異的抗体
を産するヒト・ヒトハイブリドーマ(HB4C5)を使
用し、HB4C5細胞は無血清培養法に従い、アミノ
酸、塩、糖、ビタミンを含む無血清培地(eRDF培地
等、特開平4−51891号公報参照)にITES(イ
ンシュリン、トランスフェリン、エタノールアミン、亜
セレン酸ナトリウム)を加えた培地を用い、U937は
eRDF培地に必要に応じて5%FBS(牛胎児血清)
を添加した培地を用い、それぞれ5%CO2 、37℃で
培養することにより行った。
Column size: 1.5 cm x 38 cm, flow rate: 43.8
ml / hr, buffer (start): 50 mM sodium phosphate buffer (pH 6.2) (elution): 50 mM sodium phosphate buffer (pH
6.2) NaCl at concentrations up to +0.3 mM In addition, fraction No. in Fig. 1 is 1 fraction
It is 5.9 ml per No. (Test Example 1, method for measuring cell growth promoting action) Cell culture was performed as follows. Human monocytic cells (U937) and human-human hybridomas (HB4C5) producing human lung cancer-specific antibodies were used as the cultured cells for examining the growth-promoting effect. A serum-free medium containing sugar and vitamins (eRDF medium, etc., see Japanese Patent Laid-Open No. 4-51891) with ITES (insulin, transferrin, ethanolamine, sodium selenite) is used, and U937 is required for the eRDF medium. 5% FBS (fetal bovine serum) according to
It was carried out by culturing at 37 ° C. in 5% CO 2 using the medium to which was added.

【0013】細胞増殖促進活性及び細胞成長因子活性の
有無は、ローヤルゼリー糖蛋白質の添加による生細胞数
の増加度合いにより判定した。生細胞数の測定は、MT
T〔3-4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl Tetra
zolium Bromide〕−アッセイ法により行った。このMT
T−アッセイ法はScudieroらの方法(Cancer Research
48,4827,1988)を一部改変して行った。
The presence or absence of cell growth promoting activity and cell growth factor activity was judged by the degree of increase in the number of viable cells due to the addition of royal jelly glycoprotein. The number of viable cells can be measured by MT
T [3-4,5-Dimethylthiazol-2-yl) -2,5-Diphenyl Tetra
zolium Bromide] -assay. This MT
The T-assay method is the method of Scudiero et al. (Cancer Research
48, 4827, 1988) with some modifications.

【0014】即ち、まず24穴プレートを用いて培養し
た細胞を110μl ずつ96穴プレートに分注し、MT
T試薬を20μl ずつ加えた。4〜5時間反応させた
後、遠心分離し、上清を除去した沈澱に100μl の0.
04規定塩酸を含むイソプロパノールを加え、540nmの
吸光度を測定することにより行った。 (試験例2、U937細胞増殖促進作用)ローヤルゼリ
ー由来のDI 画分、DII画分及びDIII 画分をそれぞれ
eRDF培地に対して0.1 μg /ml 〜 4mg/ml の範囲で
添加して無血清培地を得た。この培地を用いてU937
細胞に対しての培養を5日間行った。その結果を図2に
示す。図2に示すように、DIII 画分の生細胞数が最も
多く、最も良好な細胞増殖活性を示した。特に、DIII
画分の添加量が 2mg/ml のところでピークを示し、コン
トロール(培地としてeRDF培地に前記FBSのみを
添加した比較例)に比較して約7倍の増殖促進活性が見
られた。
That is, first, cells cultured in a 24-well plate were dispensed in 110 μl aliquots into a 96-well plate, and MT
20 μl of T reagent was added. After reacting for 4 to 5 hours, the mixture was centrifuged and the supernatant was removed.
It was carried out by adding isopropanol containing 04N hydrochloric acid and measuring the absorbance at 540 nm. (Test Example 2, U937 cell growth promoting action) The serum-free medium was prepared by adding the royal jelly-derived DI fraction, DII fraction and DIII fraction to the eRDF medium in the range of 0.1 μg / ml to 4 mg / ml. Obtained. U937 using this medium
The cells were cultured for 5 days. The result is shown in FIG. As shown in FIG. 2, the number of viable cells in the DIII fraction was the highest, and the cell proliferation activity was the best. In particular, DIII
A peak appeared when the amount of the fraction added was 2 mg / ml, and about 7 times as much growth-promoting activity as that of the control (Comparative Example in which only FBS was added to the eRDF medium as a medium) was observed.

【0015】DIII 画分に次いでDII画分が高い細胞増
殖活性を示した。DI 画分は添加量が0.1 μg /ml 〜 1
mg/ml の範囲で細胞増殖活性を示した。また、図示はし
ないが、コントロールに対して細胞成長因子活性も発現
された。
Following the DIII fraction, the DII fraction showed a high cell proliferation activity. Addition amount of DI fraction is 0.1 μg / ml 〜 1
It showed cell proliferation activity in the range of mg / ml. Although not shown, cell growth factor activity was also expressed in comparison with the control.

【0016】なお、この発明は上記実施例に限定される
ものではなく、発明の趣旨を逸脱しない範囲で例えば次
のように構成を変更して具体化してもよい。 (イ)ローヤルゼリー由来の蛋白質としてDI 画分又は
DII画分を、無血清培地に添加して細胞培養を行うこ
と。 (ロ)この発明を植物細胞の培養に適用すること。
The present invention is not limited to the above-mentioned embodiments, but may be embodied by changing the structure as follows, for example, without departing from the spirit of the invention. (A) The cell culture is performed by adding the DI fraction or DII fraction as a protein derived from royal jelly to a serum-free medium. (B) Applying the present invention to culturing plant cells.

【0017】[0017]

【発明の効果】以上詳述したようにこの発明によれば、
優れた細胞増殖促進活性等の細胞培養活性を有して効率
的な細胞培養ができる共に、生産物の分離、精製を容易
に行うことができ、しかも低コストで安定した品質のも
のを供給できるという優れた効果を奏する。
As described above in detail, according to the present invention,
Efficient cell culture can be performed with excellent cell growth promoting activity and other cell culture activities, product separation and purification can be easily performed, and stable quality products can be supplied at low cost. It has an excellent effect.

【図面の簡単な説明】[Brief description of drawings]

【図1】この発明の実施例におけるローヤルゼリー蛋白
質のフラクションNoと吸光度との関係を示すグラフで
ある。
FIG. 1 is a graph showing the relationship between the fraction No. and the absorbance of royal jelly proteins in Examples of the present invention.

【図2】同じく実施例における蛋白質量と生細胞数との
関係を示すグラフである。
FIG. 2 is a graph showing the relationship between the amount of protein and the number of viable cells in the same example.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 ローヤルゼリー由来の蛋白質を含有する
ことを特徴とする細胞培養のための無血清培地用添加組
成物。
1. An additive composition for serum-free medium for cell culture, which comprises a protein derived from royal jelly.
JP4270531A 1992-10-08 1992-10-08 Additive composition for serum-free medium Pending JPH06113828A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4270531A JPH06113828A (en) 1992-10-08 1992-10-08 Additive composition for serum-free medium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4270531A JPH06113828A (en) 1992-10-08 1992-10-08 Additive composition for serum-free medium

Publications (1)

Publication Number Publication Date
JPH06113828A true JPH06113828A (en) 1994-04-26

Family

ID=17487518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4270531A Pending JPH06113828A (en) 1992-10-08 1992-10-08 Additive composition for serum-free medium

Country Status (1)

Country Link
JP (1) JPH06113828A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4844786B2 (en) * 2000-02-15 2011-12-28 株式会社林原生物化学研究所 Cell activator
CN109608516A (en) * 2019-01-23 2019-04-12 中国农业科学院蜜蜂研究所 Rapid purification method of royal jelly major proteins 1, 2 and 3

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4844786B2 (en) * 2000-02-15 2011-12-28 株式会社林原生物化学研究所 Cell activator
CN109608516A (en) * 2019-01-23 2019-04-12 中国农业科学院蜜蜂研究所 Rapid purification method of royal jelly major proteins 1, 2 and 3
CN109608516B (en) * 2019-01-23 2020-11-27 中国农业科学院蜜蜂研究所 Rapid purification method of royal jelly major proteins 1, 2 and 3

Similar Documents

Publication Publication Date Title
TW516962B (en) A human TNFR1-IgG1 preparation
US5500229A (en) Colostrum fraction, a process of preparing it and its use as a supplement in cell culture media
US5428016A (en) Antimicrobial peptide and antimicrobial agent
HU180566B (en) Process for the microbiological production of l-threonine
US5317084A (en) Process for large-scale production of antimicrobal peptide in high purity
US20220154239A1 (en) Peptide for complexing zinc ion, complex thereof and use therefor
US20050209442A1 (en) Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
RU2054044C1 (en) Method of preparing human recombinant gamma-interferon without n-terminal methionine
JPS58192896A (en) interferon
JPH06113828A (en) Additive composition for serum-free medium
US5468635A (en) In vitro method for stimulating cell growth by culturing cells in a serum-free culture medium comprising human lysozyme
Savelkoul et al. Semi-preparative purification and validation of monoclonal antibodies for immunotherapy in mice
US4452893A (en) Cell growth medium supplement
EP0366532B1 (en) Medical preparations containing glycosylated interleukin-2
CN115537442A (en) Yolk phosphopeptide, and efficient enrichment preparation method and application thereof
JPH0432078B2 (en)
CN1166688C (en) Method of separating lactotransferrin from whey liquid
JP2947481B2 (en) Antibody production promoting substance and antibody production method
CN102443055A (en) Purification process of recombinant human tumor necrosis factor related apoptosis inducing ligand
JP2897043B2 (en) Complete synthetic medium
Brown et al. Applications of the mass culturing technique (MCT) in the large scale growth of mammalian cells
JPS59162880A (en) Production of plasminogen activator
RU2183971C2 (en) Method of immunoglobulin preparation preparing
CN1557939A (en) Growth factor containing cell culture solution additive
KR920008378B1 (en) Method for Purifying Human Insulin-like Growth Factor-I